Loading company filing…
Find a company. Follow its revenue through costs and profit.
Coverage includes separate ticker and security records; counts are not unique companies.
Sankey diagram of Noile-Immune Biotech Inc.. A complete text table follows the diagram.
R&D and corporate costs are visible while the company remains loss-making in the packet.
Swipe to explore
Every category amount is a reported EDINET XBRL fact. Nodes described as arithmetic bridges are calculated residuals and do not imply a separately reported filing line.
Labels and narrative explain the filing. A category marked “arithmetic bridge” or “residual” is calculated from reported totals, rather than a separately reported line.
| Category | Stage | Value | Notes |
|---|---|---|---|
| General and administrative expenses | 1 | 221M | 53.0% of reported total |
| Research and development costs | 1 | 196M | 47.0% of reported total |
| Other and rounding | 1 | 0 | 0.0% of reported total |
| Pre-revenue biotech operating costs | 2 | 417M | Reported six-month total · ¥417M |
| Operating loss | 2 | 413M | Absolute value of reported operating loss |
| Operating costs & expenses | 3 | 829M | Revenue plus reported operating loss |
| From | To | Value |
|---|---|---|
| General and administrative expenses | Pre-revenue biotech operating costs | 221M |
| Research and development costs | Pre-revenue biotech operating costs | 196M |
| Other and rounding | Pre-revenue biotech operating costs | 0 |
| Pre-revenue biotech operating costs | Operating costs & expenses | 417M |
| Operating loss | Operating costs & expenses | 413M |